.Kaufmann, P., Pariser, A. R. & Austin, C. From scientific exploration to procedures for rare diseasesu00e2 $" the viewpoint coming from the National Facility for Evolving Translational Sciencesu00e2 $" Workplace of Rare Diseases Research Study. Orphanet J. Rare Dis. 13, 196 (2018 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Crooke, S. T. A phone call to arms versus ultra-rare conditions. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Vockley, J. et al. The developing part of medical geneticists in the era of gene treatment: an urgency to prep. Genet. Medication. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide treatment for an unusual genetic condition. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. A structure for individualized splice-switching oligonucleotide therapy. Nature 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lima, W. F. et cetera. Human RNase H1 differentiates in between refined variants in the design of the heteroduplex substratum. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X.-H. Antisense modern technology: a guide as well as program. Nat. Rev. Medication Discov. Twenty, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lee, J.-R. et cetera. Afresh mutations in the motor domain of KIF1A trigger cognitive issue, spastic paraparesis, axonal neuropathy, as well as cerebellar degeneration. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Boyle, L. et cetera. Genotype and defects in microtubule-based mobility connect with scientific intensity in KIF1A-associated nerve problem. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Electric motor healthy protein KIF1A is essential for hippocampal synaptogenesis as well as learning augmentation in an enriched environment. Neuron 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Guo, Y. et al. An uncommon KIF1A missense mutation improves synaptic function and raises confiscation task. Face. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kaur, S. et cetera. Development of the phenotypic range of de novo missense versions in kinesin relative 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Canivez, G. L. & McGill, R. J. Variable structure of the Differential Capability Scales-Second Version: exploratory as well as hierarchical factor studies along with the primary subtests. Psychol. Examine. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Epstein, A. et al. Content recognition of the quality of life inventoryu00e2 $" handicap. Day Care Health Dev. 45, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Lek, M. et al. Review of protein-coding hereditary variety in 60,706 humans. Attribute 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medicine Products for Severely Devastating or Life-Threatening Ailments: Clinical Referrals (United States Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Articles for Tailored Antisense Oligonucleotide Medicine Products: Managerial and Step-by-step Referrals Guidance for Sponsor-Investigators (US Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Medicine Request Submittings for Personalized Antisense Oligonucleotide Drug Products for Severely Exhausting or even Deadly Conditions: Chemical Make Up, Manufacturing, and Controls Recommendations, Advice for Sponsor-Investigators (United States Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Screening of Individualized Antisense Oligonucleotide Drug Products for Drastically Debilitating or even Dangerous Conditions Assistance for Sponsor-Investigators (United States Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.